Stent Thrombosis With Drug-Eluting Stents

First-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel revascularization compared with bare metal stents (BMS). However, stent...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2013-11, Vol.62 (21), p.1915-1921
Main Authors: Palmerini, Tullio, MD, Biondi-Zoccai, Giuseppe, MD, Della Riva, Diego, MD, Mariani, Andrea, MD, Genereux, Philippe, MD, Branzi, Angelo, MD, Stone, Gregg W., MD
Format: Article
Language:English
Subjects:
bare-metal stent(s)
Cardiology
Cardiovascular
drug-eluting stent(s)
Heart attacks
Internal Medicine
Mortality
Polymers
Stents
stent thrombosis
Thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:First-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel revascularization compared with bare metal stents (BMS). However, stent thrombosis (ST) emerged as a major safety concern with first-generation DES early after their adoption in clinical practice, requiring prolonged dual antiplatelet therapy. Pathological studies have shown that first-generation DES are associated with delayed arterial healing and polymer hypersensitivity reactions resulting in chronic inflammation, predisposing to late and very late ST. Second-generation DES have been developed to overcome these issues with improved stent designs and construction and the use of biocompatible and bioabsorbable polymers. Meta-analyses have shown that the thin-strut, fluoropolymer-coated cobalt-chromium everolimus-eluting stent (CoCr-EES) may be associated with lower rates of definite ST than other DES and, unexpectedly, even lower than BMS. The thin-strut structure of the stent platform, the thromboresistant properties of the fluoropolymer, and the reduced polymer and drug load may contribute to the low rate of ST with CoCr-EES. The notion of DES being safer than BMS represents a paradigm shift in the evolution of percutaneous coronary intervention. The relative safety and efficacy of fluoropolymer-coated CoCr-EES, DES with bioabsorbable polymers, and fully bioresorbable scaffolds are the subject of numerous ongoing large-scale trials.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2013.08.725